Marksans Pharma has announced its financial results for the first quarter, revealing a mixed performance with revenue growth but a decline in profitability.

Revenue Growth

The pharmaceutical company reported a 5% year-over-year increase in operating revenue, reaching ₹620.00 crore compared to ₹590.60 crore in the same quarter last year. This growth was primarily driven by the company's performance in the US market, where new product launches in gastrointestinal, pain management, and digestive health segments contributed significantly.

Profitability Decline

Despite the revenue growth, Marksans Pharma experienced a substantial decline in its bottom line. The company's consolidated net profit decreased by 34.7% year-over-year to ₹58.20 crore, down from ₹89.10 crore in the same period last year.

EBITDA and Margin Compression

The company's EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) saw a significant decrease of 22% year-over-year, falling to ₹100.10 crore from ₹128.40 crore in the previous year. Consequently, the EBITDA margin compressed to 16.1% from 21.7% in the corresponding quarter of the previous year.

Segment Performance

Management Commentary

Mark Saldanha, Managing Director of Marksans Pharma, commented on the results: "While Q1 was a seasonally soft quarter, we delivered year-on-year revenue growth of 5%, while gross profit increased by 8.9%. This was supported by successful new product launches in the US markets and the easing of raw material costs."

He further added, "While EBITDA and net profit margins were impacted by ramp-up costs, a one-time ECL provision for the emerging market division, and forex adjustments, these are transient and do not affect the fundamental momentum of our business."

Future Outlook

Saldanha expressed optimism about the company's future prospects, stating, "We are already seeing encouraging early signs of demand recovery in key markets such as the U.S., U.K., and Australia. With the Goa facility integration nearing completion, we are now sharply focused on scaling capacity, enhancing operational efficiency, and unlocking synergies."

The company's management remains committed to driving growth, improving returns, and creating enduring value for stakeholders.

Financial Position

As of the end of the quarter, Marksans Pharma maintained a strong cash position of ₹711.00 crore, which the company believes will support its growth initiatives.

Investors and stakeholders can access more detailed financial information on the company's website at http://www.marksanspharma.com/quarterly-results.html .

Marksans Pharma Limited, a prominent player in the pharmaceutical industry, has announced the re-appointment of Mark Saldanha as its Managing Director for another five-year term. The decision, made by the company's Board of Directors, is subject to shareholder approval at the upcoming Annual General Meeting.

Leadership Continuity

Mark Saldanha, who has been instrumental in shaping Marksans Pharma's success, will continue to lead the company from October 6, 2025. This re-appointment underscores the board's confidence in Saldanha's leadership and vision for the company's future growth.

Extensive Experience

With over 24 years of experience in production, marketing, and finance, Saldanha is described as the principal architect of Marksans Pharma's success and progress. His dynamic leadership has been credited with driving the company to new heights of success and higher levels of performance.

Terms of Appointment

The re-appointment is for a five-year term, effective from October 6, 2025. Notably, Saldanha's position will not be subject to retirement by rotation, ensuring stability in the company's top leadership.

Remuneration Package

The board has approved a comprehensive remuneration package for Saldanha, which includes:

This amounts to an annual remuneration of Rs. 6,00,00,000.00. The package also includes various perquisites such as a fully furnished residential house, reimbursement of house maintenance expenses, club membership, and retirement benefits.

Corporate Governance

The re-appointment aligns with Marksans Pharma's commitment to corporate governance. The decision was made based on recommendations from the Nomination and Remuneration Committee and has received approval from the Audit Committee of Directors.

Family Ties

It's worth noting that Mark Saldanha is related to Mrs. Sandra Saldanha, indicating a family presence in the company's leadership.

Shareholder Approval

The re-appointment and remuneration package will be presented for shareholder approval at the 33rd Annual General Meeting scheduled for August 8, 2025. The company has added this as a special resolution to the AGM agenda.

This re-appointment signals Marksans Pharma's intent to maintain its current leadership structure and continue its growth trajectory under Mark Saldanha's stewardship for the next five years.